drugset / Trial / NCT05354453
A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial starts the clinical development of BI 1839100. Effects of single rising doses of BI 1389100 on safety, tolerability and pharmacokinetics will be assessed as basis for further development in patients with pulmonary fibrosis.
Timeline
- Start
- 2022-05-23
- Primary completion
- 2023-06-14
- Completion
- 2023-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 1839100 | Unknown | — | Oral |
Indications
No indication recorded.